HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cough And Cold Symptoms, Some Coming From Omicron, Sound Like Seasonal Rebound To Perrigo

Consumer Health Product Firm Notes Potential Sales Impact From Russia’s Invasion Of Ukraine

Executive Summary

Sales growth generated in October-December period and growing incidences of flu and cough/cold symptoms are harbingers for Perrigo in 2022. Sales during January and February in Russia and Ukraine tracked with $10m to $15m operating income firm anticipates there for 2022, “but it's really too early to estimate the potential full-year impact,” CEO Murray Kessler says.

You may also be interested in...



Silcock’s Work As Perrigo CFO Is Done With Firm Transitioned Entirely To Self-Care

With Raymond Silcock’s work at Perrigo linked to CEO Murray Kessler’s time with the firm and with the two working together previously as CFO and CEO at a tobacco firm, whether Kessler continues at the helm could become a topic of shareholder interest.

HRA Pharma Posts Big Rise As Key Brands Grow Double Digits

Paris-based HRA Pharma reported significant sales gains for its key consumer health brands in 2021, helping to lift group turnover by more than 25%. This is likely to be the last set of results posted by HRA as a standalone company with Perrigo optimistic its proposed acquisition of the firm will soon complete.

GSK Consumer Split Set For July, With Emerging Markets And Switch To Drive Growth

GSK will spin-off its consumer health business in July under the name Haleon. The standalone operation expects to outpace market growth rates by expanding in emerging markets, tapping into consumer demand for more natural products and delivering two Rx-to-OTC switches in the US.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

RS152260

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel